CompletedNCT00890474Updated Apr 29, 2009

Moxibustion for Fetus in Breech Presentation

A Phase 3 interventional study of Moxibustion of the BL67 acupoint in Breech Presentation, sponsored by University Hospital, Geneva. Completed at 1 site in Switzerland. Open to female participants. Per ClinicalTrials.gov, last updated 2009-04-29.

Sponsored by University Hospital, Geneva · Phase 3, Interventional, and Treatment

Phase: Phase 3
Study type: Interventional
Enrollment: 212
Allocation: Randomized
Sex: Female

Study summary

Objective: To evaluate moxibustion of the BL67 acupoint between 34 and 38 weeks of gestation to facilitate cephalic version of breech presentation in a Western setting. The hypothesis is that moxibustion increase the likelihood of cephalic version.

Design: Randomised controlled trial Setting: University hospital. Population: A total of 212 consenting women between 34 and 36 weeks of gestation with a single fetus in breech presentation will be randomised to moxibustion (n=106) or expectant management (n=106).

Main Outcome Measure: Cephalic presentation at delivery or before external cephalic version.

Conditions studied

Breech Presentation

Browse trials for

Breech Presentation 41

Keywords

Breech presentation at 34 to 36 weeks of gestation

In context

Breech Presentation

41 studies on the registry are indexed under Breech Presentation; 10 are open to participants now.

This study's enrollment of 212 is above the median of 119 across 31 interventional studies indexed under Breech Presentation.

Browse Breech Presentation studies →

Lead sponsor

University Hospital, Geneva is the lead sponsor of 379 studies on the registry; 70 are open to participants now.

Browse University Hospital, Geneva studies →

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible: Female
Accepts healthy volunteers: No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Breech presentation
34 to 36 weeks of gestation
Single fetus

Exclusion criteria

Exclusion Criteria:

Uterine malformation
Placenta praevia
Transverse lie

Study design

Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Single (Care provider)
Enrollment: 212 participants (actual)

Study arms

Experimental
Moxibustion
Procedure: Moxibustion of the BL67 acupoint
No intervention
Control

Interventions

ProcedureMoxibustion of the BL67 acupoint
Moxibustion sessions every day (every other day in hospital, self-administration at home the other day) during a maximum of 14 days. Stopped if cephalic version.

What researchers measure

Primary outcomes

Cephalic presentation at delivery or before external cephalic version
Time frame: end of pregnancy

Secondary outcomes

Mode of delivery
Time frame: end of pregnancy
Women's views on the intervention
Time frame: end of pregnancy
External cephalic version
Time frame: end of pregnancy

Study locations

1 site

Hôpitaux Universitaires de Genève
Geneva, Switzerland

References and documents

Publications

Guittier MJ, Pichon M, Dong H, Irion O, Boulvain M. Moxibustion for breech version: a randomized controlled trial. Obstet Gynecol. 2009 Nov;114(5):1034-1040. doi: 10.1097/AOG.0b013e3181bc707a. PubMed 20168104 ↗

Timeline

Tracking since Sep 25, 2026

Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2004, a primary completion of Dec 2008 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered: Apr 28, 2009
First posted: Apr 29, 2009
Start: Oct 2004
Primary completionActual: Dec 2008
CompletionActual: Jan 2009
Last update: Apr 29, 2009

What these dates mean

Start.: When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.: When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.: When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.: Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.

No changes since tracking began. The registry record was last updated on Apr 29, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT00890474
Lead sponsor: University Hospital, Geneva
Collaborators: Swiss National Science Foundation, Loterie Romande
First posted: Apr 29, 2009
Start date: Oct 2004
Primary completion: Dec 2008
Completion: Jan 2009
Last update: Apr 29, 2009

Oversight

Data monitoring committee: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Breech Presentation →

Other studies from this sponsor

University Hospital, Geneva →

Start the discussion